Viela Bio

Product Candidates

Pipeline

Targeting Autoimmune and Inflammatory Diseases Via Critical Biological Pathways

Autoimmune diseases are the result of an individual’s immune system attacking its own healthy cells and tissue. These diseases often involve autoreactive T cells and B cells, which communicate through shared biological pathways. In a healthy individual, these T cells and B cells are eliminated or suppressed. If these processes fail, however, autoantibodies—a product of autoreactive B cells—may form resulting in recurring bouts of disease flares followed by periods of remission.

At Viela Bio, we are developing a pipeline of novel therapies that address a wide range of autoimmune and severe inflammatory diseases. Our approach focuses on shared critical biological pathways to target the underlying cause of autoimmune disease. The U.S. FDA has accepted for review our Biologics License Application (BLA) for inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and we are currently preparing for the drug candidate’s potential commercialization. NMOSD is a rare condition that attacks the optic nerve, spinal cord and brain stem and often leads to irreversible blindness and paralysis.

Our pipeline also includes product candidates designed to treat myasthenia gravis, IgG4-related disease, Sjögren’s syndrome, and kidney transplant rejection, among other indications.

Pipeline Chart

Molecule
(mechanism)
IndicationDevelopment StagePotential Future
Milestone
Global
Rights
PRECLINICALPHASE 1PHASE 2PHASE 3    BLA    
Inebilizumab
(Anti-CD19 mAb)
Molecule
(mechanism)
PRECLINICALPHASE 1PHASE 2PHASE 3    BLA    
Inebilizumab
(Anti-CD19 mAb)

Neuromyelitis Optica
Spectrum Disorder

1H20: Potential
BLA Approval

Viela Bio
Potential Future
Milestone

1H20: Potential
BLA Approval

Global
RightsViela Bio

Kidney Transplant
Desensitization

2H19: Initiate
Phase 2 Trial

Viela Bio
Potential Future
Milestone

2H19: Initiate
Phase 2 Trial

Global
RightsViela Bio

Myasthenia Gravis

2020: Submit IND &
Initiate Pivotal Trial

Viela Bio
Potential Future
Milestone

2020: Submit IND &
Initiate Pivotal Trial

Global
RightsViela Bio

IgG4-Related
Disease

2020: Submit IND &
Initiate Phase 2b Trial

Viela Bio
Potential Future
Milestone

2020: Submit IND &
Initiate Phase 2b Trial

Global
RightsViela Bio
 
VIB4920
(Anti-CD40L-Tn3
Fusion Protein)
Molecule
(mechanism)
PRECLINICALPHASE 1PHASE 2PHASE 3    BLA    
VIB4920
(Anti-CD40L-Tn3
Fusion Protein)

Kidney Transplant
Rejection

2H19: Initiate
Phase 2 Trial

Viela Bio
Potential Future
Milestone

2H19: Initiate
Phase 2 Trial

Global
RightsViela Bio

Sjögren's Syndrome

2H19: Submit IND &
Initiate Phase 2 Trial

Viela Bio
Potential Future
Milestone

2H19: Submit IND &
Initiate Phase 2 Trial

Global
RightsViela Bio
 
VIB7734
(Anti-ILT7 mAb)
Molecule
(mechanism)
PRECLINICALPHASE 1PHASE 2PHASE 3    BLA    
VIB7734
(Anti-ILT7 mAb)

Cutaneous Lupus
Erythematosus2

1H2020: Phase 1b
Interim Data

Viela Bio
Potential Future
Milestone

1H2020: Phase 1b
Interim Data

Global
RightsViela Bio
 

1 We have entered into collaboration agreements with Hansoh Pharmaceutical Group and Mitsubishi Tanabe Pharma to develop and market inebilizumab in China, Hong King and Macau and Japan and other Asia regions, respectively.​

2 This indication is one of six potential indications being studied in our ongoing Phase 1b multiple ascending dose trial, along with systemic lupus erythematous, Sjögren’s syndrome, systemic sclerosis, polymyositis and dermatomyositis.